https://www.live-feeds.com/feed/moderna-merck-breakthrough-could-usher-in-wave-of-cancer-vaccinesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-merck-breakthrough-could-usher-in-wave-of-cancer-vaccineshttps://www.live-feeds.com/feed/moderna-merck-breakthrough-could-usher-in-wave-of-cancer-vaccines#u48932Wed, 26 Aug 2026 08:00:19 +0000Moderna and Merck have developed an mRNA vaccine called intismeran that reduces the risk of melanoma recurrence. The vaccine passed a Phase 3 trial when used in combination with the drug Keytruda. This development follows a decade of research where the companies navigated pandemic obstacles and logistical challenges. The success has increased Moderna's share price and created potential financial opportunities for five other biotech companies involved in the manufacturing process.Why it mattersPersonalized cancer vaccines aim to prevent the return of tumors after initial treatment. This br https://www.live-feeds.com/feed/moderna-merck-breakthrough-could-usher-in-wave-of-cancer-vaccineshttps://www.live-feeds.com/feed/moderna-merck-breakthrough-could-usher-in-wave-of-cancer-vaccines#u46503Sun, 23 Aug 2026 00:25:49 +0000Moderna and Merck's mRNA vaccine, tested in a large trial, shows promise in preventing melanoma from returning. The vaccine, known as intismeran, was found to lower the risk of skin cancer recurrence. This breakthrough could potentially usher in a wave of cancer vaccines. The vaccine's success has led to a significant surge in Moderna's shares.Why it mattersThe trial's success is a significant development in the fight against cancer, particularly melanoma, a type of skin cancer. The use of mRNA technology, also used in COVID-19 vaccines, is being explored for its potential